Future Oncology, Volume 19, Issue 35 (2023)

Browse this journal
Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days

Future Oncology, Volume 19, Issue 35 (2023)

See all volumes and issues
Vol 20, 2024 Volume 19, 2023 Vol 18, 2022 Vol 17, 2021 Vol 16, 2020 Vol 15, 2019 Vol 14, 2018 Vol 13, 2017 Vol 12, 2016 Vol 11, 2015 Vol 10, 2014 Vol 9, 2013 Vol 8, 2012 Vol 7, 2011 Vol 6, 2010 Vol 5, 2009 Vol 4, 2008 Vol 3, 2007 Vol 2, 2006 Vol 1, 2005
Download citations Download PDFs Download issue

Letter to the Editor

Letter to the Editor
Response to “Hedgehog pathway inhibitor real-world treatment patterns in patients with basal cell carcinoma: a claims-based analysis”
Florian Herms & Nicole Basset-Seguin
Pages: 2335-2336
Published online: 15 Nov 2023
CitationforResponse to “Hedgehog pathway inhibitor real-world treatment patterns in patients with basal cell carcinoma: a claims-based analysis” | Full Text | References | PDF (1.2 MB) | EPUB
  • 13 Views
  • 0 CrossRef citations
  • 0Altmetric

Letter in Reply

Reply
Response to letter to editor on the article: Ge W, Chen C, Wu N et al. Hedgehog pathway inhibitor real-world treatment patterns in patients with basal cell carcinoma: a claims-based analysis. Fut. Oncol. 18(23), 2561–2572 (2022)
Wenzhen Ge, Chieh Chen, Ning Wu, Matthew G Fury, Emily Ruiz & Jessica J Jalbert
Pages: 2337-2339
Published online: 14 Nov 2023
First Page PreviewforResponse to letter to editor on the article: Ge W, Chen C, Wu N et al. Hedgehog pathway inhibitor real-world treatment patterns in patients with basal cell carcinoma: a claims-based analysis. Fut. Oncol. 18(23), 2561–2572 (2022) | Full Text | References | PDF (1.2 MB) | EPUB
  • 23 Views
  • 0 CrossRef citations
  • 0Altmetric

Plain Language Summary of Publication

Plain Language Summary of Publication
Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with HR+, HER2+ advanced breast cancer: plain language summary of the monarcHER study
Sara M Tolaney, Shom Goel, Adams Kusi Appiah, Trish Huynh, Yanyun Chen & Fabrice André
Pages: 2341-2348
Published online: 03 Oct 2023
AbstractforAbemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with HR+, HER2+ advanced breast cancer: plain language summary of the monarcHER study | PDF (3 MB)
  • 1497 Views
  • 0 CrossRef citations
  • 0Altmetric
Open Access

Clinical Trial Protocol

Review Article
TROPION-Breast02: Datopotamab deruxtecan for locally recurrent inoperable or metastatic triple-negative breast cancer
Rebecca A Dent, David W Cescon, Thomas Bachelot, Kyung Hae Jung, Zhi-Ming Shao, Shigehira Saji, Tiffany A Traina, Petra Vukovic, Darlington Mapiye, Micah J Maxwell, Peter Schmid & Javier Cortés
Pages: 2349-2359
Published online: 01 Aug 2023
AbstractforTROPION-Breast02: Datopotamab deruxtecan for locally recurrent inoperable or metastatic triple-negative breast cancer | Full Text | References | PDF (1.7 MB) | EPUB
  • 7854 Views
  • 2 CrossRef citations
  • 0Altmetric
Open Access

Short Communication

Brief Report
Prognostic impact of early ctDNA dynamics during chemotherapy of metastatic cancer
Louise Faaborg, Rikke Fredslund Andersen, Sara WC Wen, Caroline B Thomsen, Louise Raunkilde, Torben Frøstrup Hansen, Lars Henrik Jensen, Karina Dahl Steffensen & Anders Jakobsen
Pages: 2361-2367
Published online: 15 Nov 2023
AbstractforPrognostic impact of early ctDNA dynamics during chemotherapy of metastatic cancer | Full Text | References | PDF (1.4 MB) | EPUB
  • 49 Views
  • 0 CrossRef citations
  • 0Altmetric

Review

Review Article
Revolutionizing colorectal cancer treatment: unleashing the potential of miRNAs in targeting cancer stem cells
George Yiadom Osei, Joseph Adu-Amankwaah, Selina Koomson, Solomon Beletaa, Muhammad Khairi Ahmad, Emmanuel Akomanin Asiamah, Cecilia Smith-Togobo & Siti Razila Abdul Razak
Pages: 2369-2382
Published online: 16 Nov 2023
AbstractforRevolutionizing colorectal cancer treatment: unleashing the potential of miRNAs in targeting cancer stem cells | Full Text | References | PDF (5.6 MB) | EPUB | Supplemental
  • 86 Views
  • 0 CrossRef citations
  • 0Altmetric

Explore articles

Explore the most recently published articles

STELLAR-303: randomized phase III study of zanzalintinib + atezolizumab in previously treated metastatic colorectal cancer
Anwaar Saeed et al.
Method | Published online: 23 Jul 2024
Gastric cancer in pregnancy: a review
Hongming Liu et al.
Review Article | Published online: 23 Jul 2024
A novel prognostic index for extranodal natural killer/T-cell lymphoma in the era of pegaspargase/L-asparaginase
Ziyuan Shen et al.
Article | Published online: 23 Jul 2024
An investigator-initiated clinical study in patients with refractory or recurrent solid tumors: ‘R-ISV-FOLactis’ trial
Juanjuan Dai et al.
Method | Published online: 21 Jul 2024
View all latest articles